Nasus Pharma is trading at $4.09, up +7.21%, alongside a broader risk-on session; no company-specific cause has been established.
- Major U.S. indexes are higher after softer-than-expected September jobs data eased rate-hike concerns.
- Nasus Pharma’s latest announcement, on September 29, reported the first patient enrolled and dosed in its NS003 Phase 1 study; topline pharmacokinetic data are expected in Q4 2026. No new October 2 company announcement was found.